Hinduja Global Solutions Announces Q2 FY2022 Results
The performance was driven by robust growth in revenues and margins of our UK business, our digital business as well as the healthcare business. Strong revenue growth coupled with savings from the hybrid working model helped us mitigate challenges arising from talent supply constraints to report increased EBITDA margins in Q2.
Hinduja Global Solutions (HGS) (listed in BSE & NSE) today announced its unaudited Second Quarter Results for FY2022.
Speaking on the results, Partha DeSarkar, Executive Director and Global CEO of HGS said: “HGS reported excellent performance in Q2 FY2022. Overall revenue for the quarter stood at Rs. 15,826 million, an increase of 18.8% YoY, while EBITDA grew by 21.2% YoY to Rs 2,269 million and PAT by 67.9% YoY to Rs 1,365 million.
The performance was driven by robust growth in revenues and margins of our UK business, our digital business as well as the healthcare business. Strong revenue growth coupled with savings from the hybrid working model helped us mitigate challenges arising from talent supply constraints to report increased EBITDA margins in Q2.
Today’s market continues to witness a strong demand for high value customer experience services. Our sustained investments in priority verticals, such as the UK public sector, and the 3As (automation, analytics and AI) in a cloud first model are creating newer opportunities for us. Clients want engagements that help them innovate, optimize and grow. The deals we have won in the last few months and our healthy pipeline exemplify this trend. Going forward, our strategy is to continue to invest in intelligently integratingpeople with technology to design enhanced experiences and position HGS as a preferred growth partner for our clients.”
Update on the divestment of the Healthcare Services business:
HGS’ Board of Directors at its meeting held on August 9, 2021 approved and entered into definitive agreements to sell the Healthcare Services business to the subsidiaries of Betaine BV, which is owned by funds affiliated with Baring Private Equity Asia (BPEA). The transaction is based on an enterprise value of US$ 1,200 million and subject to closing adjustments, shareholder and other regulatory approvals. The divestment has been approved by the shareholders at the meeting held on September 23, 2021. The Company along with Betaine BV and its subsidiaries (the Buyer) are in the process of obtaining the required regulatory approvals in multiple geographies to complete the above transaction.
· Q2 FY2022 revenues stood at Rs. 15,826 million, a growth of 18.8% YoY.
· EBITDA for Q2 FY2022 was Rs. 2,269 million, a growth of 21.2% YoY.
· EBITDA margins stood at 14.3% in Q2 FY2022.
· Net profit for Q2 FY2022 was Rs. 1,365 million, a growth of 67.9% YoY; Net margins stood at 8.6%.
· Capital expenditure for the quarter was Rs. 744 million.
· Reduction in gross debt of Rs.345 million in Q2 FY2022; As on September 30, 2021, Net Cash stood at Rs. 5,008 million.
· Second Interim Dividend of Rs. 10/share.
· Revenues increased to Rs. 31,331 million, a growth of 22.0% YoY.
· EBITDA stood at Rs. 4,590 million, a growth of 37.9% YoY. EBITDA margins was 14.6%.
· Net profit stood at Rs. 2,535 million, a growth of 94.2% YoY. Net margins was 8.1%.
